Jyong Biotech Ltd. (NASDAQ:MENS) Sees Large Decline in Short Interest

Jyong Biotech Ltd. (NASDAQ:MENS) was the recipient of a large decline in short interest in June. As of June 30th, there was short interest totaling 208,547 shares, a decline of 36.2% from the June 15th total of 327,052 shares. Based on an average daily volume of 188,004 shares, the short-interest ratio is presently 1.1 days. Approximately 0.3% of the company’s shares are sold short.

Hedge Funds Weigh In On Jyong Biotech

A number of hedge funds have recently modified their holdings of the stock. Jane Street Group LLC purchased a new position in Jyong Biotech in the fourth quarter valued at about $275,000. Millennium Management LLC raised its stake in shares of Jyong Biotech by 209.4% during the 4th quarter. Millennium Management LLC now owns 40,258 shares of the company’s stock worth $159,000 after purchasing an additional 27,245 shares in the last quarter. Man Group plc acquired a new stake in shares of Jyong Biotech during the 4th quarter valued at about $56,000. China Universal Asset Management Co. Ltd. bought a new stake in shares of Jyong Biotech in the 4th quarter valued at approximately $49,000. Finally, Geode Capital Management LLC increased its holdings in Jyong Biotech by 19.6% in the fourth quarter. Geode Capital Management LLC now owns 64,382 shares of the company’s stock worth $254,000 after buying an additional 10,538 shares during the last quarter.

Jyong Biotech Trading Down 1.7%

Shares of MENS opened at $2.26 on Friday. The business’s 50-day moving average is $2.02 and its 200-day moving average is $2.32. Jyong Biotech has a fifty-two week low of $1.43 and a fifty-two week high of $67.00.

Jyong Biotech (NASDAQ:MENS) last announced its quarterly earnings data on Friday, May 15th. The company reported ($0.02) EPS for the quarter.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Jyong Biotech in a research report on Friday, May 22nd. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock presently has an average rating of “Sell”.

Jyong Biotech Company Profile

OUR MISSION We endeavor to develop and supply first-class innovative drugs to meet our customers’ health needs. We seek to be a valuable business organization that is held in high esteem by the public. We are a science-driven biotechnology company based in Taiwan and are committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU, and Asia.